Table 3B.
Most utilized biotech drugs in HG, DM, RT, and NE Units: occurrence and seriousness of adverse event.
| Hepato-gastroenterology Unit N. enrolled patients 77 | Dermatology Unit N. enrolled patients 32 | Rheumatology Unit N. enrolled patients 219 | Neurology Unit N. enrolled patients 14 | ||||
|---|---|---|---|---|---|---|---|
| Diagnosis N. pt (% on population enrolled in each Clinic Unit) | Crohn disease 41 (53.2) | Ulcerative colitis 36 (46.7) | Psoriasis 32 (100) | Rheumatoid arthritis 130 (59.4) | Psoriatic arthritis 51 (23.3%) | Other# 38 (17.4) | Multiple sclerosis 14 (100%) |
| Biologic drug (N. of users, % patient with AEs, N. of AEs reported) | Infliximab (30, 56.7%, 124) Adalimumab (11, 36.4%, 30) | Infliximab (33, 45.5%, 42) Adalimumab (2, 100%, 2) | Etanercept (13, 15.4%, 4) Adalimumab (12, 50.0%, 14) Ustekinumab (6, 16.7%, 2) | Tocilizumab (36, 22.2%, 23) Abatacept (20, 40.0%, 44) Etanercept (17, 12.5%, 15) Golimumab (12, 23.1%, 13) Adalimumab (13, 7.7%, 3) Certolizumab pegol (12, 25%, 8) Infliximab (10, 10.0%, 3) | Adalimumab (18, 16.7%, 26) Etanercept (12, 33.3%, 11) Golimumab (9, 11.1%, 1) | Adalimumab (10, 30%, 16) Rituximab (4, 25%, 5) infliximab (3, 33.3%, 2) | Natalizumab (14, 42.9%, 9) |
| Serious AE by biologic drug (%) | Infliximab (8.1) Adalimumab (0.0) | Infliximab (19.0) Adalimumab (50.0) | Etanercept (0.0) Adalimumab (14.3) Ustekinumab (0.0) | Tocilizumab (34.8) Abatacept (9.1) Etanercept (13.3) Golimumab (15.4) Adalimumab (66.7) Certolizumab pegol (25.0) Infliximab (0.0) | Adalimumab (0.0) Etanercept (9.1) Golimumab (0.0) | Adalimumab (0.0) Rituximab (40.0) Infliximab (100.0) | Natalizumab (33.3) |
£
Other solid cancer includes: head-neck cancer (including oropharyngeal, laryngeal, brain cancers), ovarian cancer, prostatic cancer, peritoneal cancer.
#
Other: Systemic lupus erythematosus, osteoporosis, systemic vasculitis, spondyloarthritis.